We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+46.65%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1B
AUM Growth
+$220M
Cap. Flow
-$11.4M
Cap. Flow %
-1.13%
Top 10 Hldgs %
62.05%
Holding
51
New
6
Increased
3
Reduced
11
Closed
2

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$30.3M
2
CBAY
Cymabay Therapeutics
CBAY
+$12.2M
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$11.2M
4
QURE icon
uniQure
QURE
+$8.06M
5
MTNB icon
Matinas BioPharma
MTNB
+$7.34M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$56.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10.5M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$7.72M
5
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 97.66%
2 Materials 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$241M 24.02%
2,046,832
-120,000
-6% -$10.5M
CRNX icon
2
Crinetics Pharmaceuticals
CRNX
$8.88B
$76.8M 7.66%
3,375,169
-417,000
-11% -$10.2M
CDXS icon
3
Codexis
CDXS
$136M
$53.8M 5.36%
2,618,951
-95,507
-4% -$1.86M
ARWR icon
4
Arrowhead Research
ARWR
$12.1B
$42.7M 4.26%
2,328,475
– –
KALV
5
DELISTED
KalVista Pharmaceuticals
KALV
$38.9M 3.88%
1,359,149
– –
SVA
6
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 3.81%
5,900,000
– –
INSM icon
7
Insmed
INSM
$22.6B
$34M 3.39%
+1,170,290
New +$30.3M
KDMN
8
DELISTED
Kadmon Holdings, Inc.
KDMN
$33.3M 3.32%
12,606,605
+2,152,060
+21% +$5.43M
QTTB icon
9
Q32 Bio
QTTB
$467M
$32.2M 3.21%
64,430
– –
VYNE icon
10
VYNE Therapeutics
VYNE
$19.1M
$31.5M 3.14%
1,114
– –
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
$29.5M 2.94%
781,185
– –
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$27.3M 2.72%
2,056,000
+1,150,000
+127% +$12.2M
BHVN
13
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$26M 2.59%
504,980
-1,308,360
-72% -$56.5M
EIGR
14
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$25M 2.5%
59,709
– –
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18.4M 1.84%
251,107
– –
LITS
16
Lite Strategy Inc
LITS
$33M
$17.7M 1.77%
288,905
– –
KNSA icon
17
Kiniksa Pharmaceuticals
KNSA
$6.11B
$15.2M 1.52%
843,478
+578,600
+218% +$11.2M
IOVA icon
18
Iovance Biotherapeutics
IOVA
$2.1B
$15.2M 1.52%
1,600,000
– –
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.28B
$14.3M 1.42%
1,405,476
– –
ACER
20
DELISTED
Acer Therapeutics Inc
ACER
$14.1M 1.4%
579,051
– –
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
$12M 1.2%
937,147
– –
AMRS
22
DELISTED
Amyris Inc.
AMRS
$11.7M 1.16%
5,575,785
– –
QURE icon
23
uniQure
QURE
$2.52B
$10.8M 1.07%
+180,336
New +$8.06M
NBRV
24
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$10.7M 1.07%
17,615
-8,862
-33% -$4.83M
ZYME icon
25
Zymeworks
ZYME
$1.66B
$10M 1%
620,134
– –
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Vivo Capital held 51 positions worth $1B, up 28% from $783M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vivo Capital's Q1 2019 filing shows 6 new, 3 increased, 11 reduced and 2 closed positions. Its largest new stake was Insmed: 1,170,290 shares worth $34M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $56.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q1 2019 buy was Insmed: 1,170,290 shares worth $34M.
  • Vivo Capital added most to Cymabay Therapeutics in Q1 2019, an estimated $12.2M increase.
  • Vivo Capital's biggest Q1 2019 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $56.5M.
  • Vivo Capital fully exited Arvinas in Q1 2019, selling an estimated $2.69M.
  • Vivo Capital's ten largest holdings make up 62% of its $1B portfolio in Q1 2019.
  • Vivo Capital opened 6 new positions and closed 2 in Q1 2019.
  • Vivo Capital's portfolio value rose 28% quarter-over-quarter to $1B.

Based on Vivo Capital's 13F filing for Q1 2019, filed 14 May 2019.